TY - JOUR
T1 - Endophthalmitis following same-day bilateral anti-VEGF injections
T2 - a systematic review
AU - Bjerager, Jakob
AU - Hajari, Javad
AU - Klefter, Oliver Niels
AU - Subhi, Yousif
AU - Schneider, Miklos
N1 - © 2024. The Author(s), under exclusive licence to Springer Nature B.V.
PY - 2024/2/8
Y1 - 2024/2/8
N2 - PURPOSE: To review the risk of endophthalmitis in same-day bilateral anti-VEGF injections.METHODS: We searched 12 literature databases for studies on the risk of endophthalmitis after same-day bilateral intravitreal anti-VEGF injections. Data extraction was made independently by two authors and discussed afterward until reaching consensus.RESULTS: Seventeen studies were included with a total of 138,478 intravitreal anti-VEGF injections (69,239 bilateral injections sessions) given in at least 7579 patients. In total, 33 cases of endophthalmitis had occurred, and no cases were bilateral. The incidence of endophthalmitis ranged from 0 to 0.53% per intravitreal injection across studies.CONCLUSIONS: We suggest that clinicians can consider same-day treatment of both eyes of patients in need of bilateral intravitreal anti-VEGF injection therapy, but larger studies are needed to quantify the exact risk of endophthalmitis.
AB - PURPOSE: To review the risk of endophthalmitis in same-day bilateral anti-VEGF injections.METHODS: We searched 12 literature databases for studies on the risk of endophthalmitis after same-day bilateral intravitreal anti-VEGF injections. Data extraction was made independently by two authors and discussed afterward until reaching consensus.RESULTS: Seventeen studies were included with a total of 138,478 intravitreal anti-VEGF injections (69,239 bilateral injections sessions) given in at least 7579 patients. In total, 33 cases of endophthalmitis had occurred, and no cases were bilateral. The incidence of endophthalmitis ranged from 0 to 0.53% per intravitreal injection across studies.CONCLUSIONS: We suggest that clinicians can consider same-day treatment of both eyes of patients in need of bilateral intravitreal anti-VEGF injection therapy, but larger studies are needed to quantify the exact risk of endophthalmitis.
KW - Humans
KW - Ranibizumab/adverse effects
KW - Angiogenesis Inhibitors
KW - Bevacizumab/adverse effects
KW - Vascular Endothelial Growth Factor A
KW - Endophthalmitis/epidemiology
KW - Intravitreal Injections
KW - Retrospective Studies
KW - Incidence
UR - http://www.scopus.com/inward/record.url?scp=85184791009&partnerID=8YFLogxK
U2 - 10.1007/s10792-024-02983-4
DO - 10.1007/s10792-024-02983-4
M3 - Review
C2 - 38332399
SN - 0165-5701
VL - 44
JO - International Ophthalmology
JF - International Ophthalmology
IS - 1
M1 - 37
ER -